Shattuck Labs STTK 深 沪
已收盘 08-07 16:00:00 美东时间
7.27
+0.110
+1.54%
华盛通- 最 高7.42
- 今 开7.30
- 成交量 89.45万股
- 最 低 7.215
- 昨 收 7.16
- 总市值 6.94亿
- 52周最高 8.33
- 市盈率 静 --
- 换手率 0.94%
- 52周最低 0.7939
- 委 比 -1.74%
- 总股本 9550.82万
- 历史最高 60.516
- 量 比 0.92
- 振 幅 2.86%
- 历史最低 0.6922
- 每 手 1
- 风险率 2.13%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 最高120美元！大小摩等7家大行集体上调英特尔目标价；汇丰首予SpaceX"持有"评级，目标价115美元
今日重点评级关注：HC Wainwright & Co.：维持居里"买入"评级，目标价从17美元升至43美元；花旗：维持Klaviyo"买入"评级，目标价从31美元升至34美元
07-27 14:02
JP Morgan Initiates Coverage On Shattuck Labs with Overweight Rating, Announces Price Target of $10
JP Morgan analyst Brian Cheng initiates coverage on Shattuck Labs (NASDAQ:STTK) with a Overweight rating and announces Price Target of $10.
07-24 18:51
美股大行评级 | 伯恩斯坦上调Robinhood目标价从130美元升至160美元；纽约梅隆银行、Datadog、五三银行、旅行者财产险集团获多家机构上调评级
今日重点评级关注：Needham：维持Immuneering"买入"评级，目标价从11美元升至18美元；富瑞：维持塞德斯医疗"买入"评级，目标价从90美元升至100美元
07-21 11:36
美股大行评级 | 潜在涨幅321.55%！Shattuck Labs获花旗升目标价至18美元，维持"买入"评级
今日重点评级关注：花旗：维持Shattuck Labs"买入"评级，目标价从7美元升至18美元；Benchmark：维持Gloo Holdings"买入"评级，目标价从14美元升至15美元
06-10 12:32
Shattuck Labs Commences Common Stock Offering; Terms Undisclosed
Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the
06-10 04:19
Shattuck Labs Announces Total Expected Proceeds Of ~$59.4M From Exercised Warrants
Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3-blocking antibodies for the treatment of
06-09 20:05
美股大行评级 | 存储再获看多！美光、闪迪、西部数据获机构上调目标价；次新股Cerebras、Blackstone、EagleRock获多家机构首予买入平均
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5.25美元升至5.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从9美元升至9.25美元
06-09 11:33
Why Is Shattuck Labs Stock Trading Lower On Monday?
Shattuck Labs' stock tumbles after Phase 1 SL-325 data release despite analyst upgrades, a Buy consensus rating, and progress in IBD treatment.
06-09 00:40
Shattuck Reports Phase 1 Data for SL-325 Antibody
Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the
06-08 18:03
